HomeInsightsStock Comparison

Fdc Ltd vs Natco Pharma Ltd Stock Comparison

Fdc Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 21, 2025

Key Highlights

  • The Latest Trading Price of FDC Ltd is ₹ 455.25 as of 20 Jun 15:30.
  • The P/E Ratio of FDC Ltd changed from 14 on March 2020 to 22.6 on March 2024 . This represents a CAGR of 10.05% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of FDC Ltd changed from ₹ 3350 crore on March 2020 to ₹ 6912 crore on March 2024 . This represents a CAGR of 15.59% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of FDC Ltd for the Mar '25 is ₹ 507.97 crore as compare to the Dec '24 revenue of ₹ 482.94 crore. This represent the growth of 5.18% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of FDC Ltd for the Mar '25 is ₹ 70.06 crore as compare to the Dec '24 ebitda of ₹ 65.48 crore. This represent the growth of 6.99% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of FDC Ltd changed from ₹ 109.81 crore to ₹ 38.67 crore over 8 quarters. This represents a CAGR of -40.66% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of FDC Ltd changed from 5.54 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About FDC Ltd

  • FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
  • The Company is a prominent player in the Indian pharmaceutical industry, renowned for its expertise in developing specialised formulations.
  • It leads the market in sectors such as Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies.
  • It has established a global footprint in both domestic and international market, standing as a beacon of excellence in pharmaceutical and consumer healthcare industry. Promoted as a partnership firm in 1936 by the Late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods, FDC Limited was established on September 23, 1940.

About Natco Pharma Ltd

  • Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited.
  • It became a deemed public company with effect from 1 July 1992.
  • The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993.
  • The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.

FDC Ltd News Hub

News

Volumes jump at FDC Ltd counter

Bajaj Finance Ltd, P I Industries Ltd, Anand Rathi Wealth Ltd, Cipla Ltd are among the oth...

Read more

16 Jun 2025 11:00

News

FDC to conduct board meeting

FDC will hold a meeting of the Board of Directors of the Company on 28 May 2025. Powered b...

Read more

23 May 2025 17:29

News

FDC to declare Quarterly Results

FDC will hold a meeting of the Board of Directors of the Company on 12 February 2025. Powe...

Read more

08 Feb 2025 11:03

News

FDC gets USFDA nod for anti-bacterial drug

The announcement was made at the fag end of market hours yesterday. Cefixime is used to tr...

Read more

19 Dec 2024 10:47

News

Board of FDC recommends first interim dividend

FDC announced that the Board of Directors of the Company at its meeting held on 6 November...

Read more

07 Nov 2024 15:15

News

FDC schedules board meeting

FDC will hold a meeting of the Board of Directors of the Company on 6 November 2024 Powere...

Read more

29 Oct 2024 15:20

Natco Pharma Ltd News Hub

News

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 ...

Read more

20 Jun 2025 09:54

News

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483. The...

Read more

14 Jun 2025 13:45

News

Natco Pharma's Mekaguda API unit completes USFDA inspection

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active P...

Read more

13 Jun 2025 16:27

News

Natco Pharma Ltd gains for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908...

Read more

11 Jun 2025 13:05

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

SWOT Analysis Of FDC Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for FDC Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of FDC Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, FDC Ltd or Natco Pharma Ltd?

Market cap of FDC Ltd is 7,411 Cr while Market cap of Natco Pharma Ltd is 15,677 Cr

What are the key factors driving the stock performance of FDC Ltd and Natco Pharma Ltd?

The stock performance of FDC Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for FDC Ltd and Natco Pharma Ltd?

As of June 21, 2025, the FDC Ltd stock price is INR ₹455.25. On the other hand, Natco Pharma Ltd stock price is INR ₹875.3.

How do dividend payouts of FDC Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of FDC Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions